Companies ›Healthcare ›054950.KQ

054950.KQ — KOSDAQ Advanced Medical Equipment & Technology

JVM Co Ltd

$23 150,00

Open in Charts → Attach watcher ⌖

— —

USD

Set alert

Last 30 days

1D5D1M3M6MYTD1Y5YMax

Live price chart loads from the market-data widget.

Mcap

—

P/E

—

EV / Rev

—

Div yield

2,60 %

Op margin

19,2 %

ROE

12,1 %

Net margin

16,4 %

Debt / equity

0,14

Beta

—

52w range

—

Volume

—

Day range

—

Prev close

—

Open

—

Next earnings

—

Ex-dividend

—

TR 1Y

—

About

JVM Co Ltd designs, develops, and distributes advanced medical equipment and technology, primarily serving the healthcare sector.

Business. JVM Co Ltd (054950.KQ) is a South Korean company engaged in the Advanced Medical Equipment & Technology industry within the broader Healthcare Services & Equipment sector. The firm operates primarily through a product-sale revenue model, focusing on the development and distribution of advanced medical devices. It is listed on the KOSDAQ exchange. Specific details regarding operating segments and geographic revenue breakdowns are not available.

Classification92 %

SectorHealthcare

Business sectorHealthcare Services & Equipment

IndustryAdvanced Medical Equipment & Technology

Generated · model-assisted

Sell-side consensus

BUY5 analysts

5 buy0 hold0 sell

Avg 12m price target34 333,33

Analyst recommendations

5 analysts · consensus Buy

Buy5

Hold0

Sell0

12-month price target

34 333,33

Consensus of sell-side coverage.

Upcoming events

— missing data

See all catalysts →

At a glance

Score

—

not yet scored

Valuation

—

valuation pending

Analysts→

Buy

5 analysts · indicative

Ownership

—

not yet wired

Profitability→

12,1 %

return on equity

Quality

—

not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

No recent newsroom coverage mentioning 054950.

Sector rotation

Sector1D1Mvs mkt

Materials+2,3 %+6,6 %+1,7 %

Communication Services+2,2 %−5,5 %+1,6 %

Energy+0,6 %+3,3 %+0,0 %

Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %

Information Technology+0,6 %+6,7 %+0,0 %

Consumer Discretionary+0,4 %+7,6 %−0,2 %

Financials−0,3 %−2,8 %−0,9 %

Consumer Staples−0,4 %+2,5 %−1,0 %

Real Estate−0,7 %+10,9 %−1,3 %

Industrials−1,9 %−3,1 %−2,5 %

Utilities−1,9 %+28,2 %−2,5 %

Developing storylines

No tracked sagas currently linked to 054950.KQ. Browse all sagas →

Analysis

AI analysis

Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

Opportunity

— missing data

Upcoming catalysts

Scheduled public events. Informational only — not investment advice.

Macro
Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
Macro & political
ElectionSE Swedish Election2026-09-14 · SE
ElectionUS U.S. Midterms2026-11-03 · US
ElectionFR French Legislative2027-06-01 · FR

Pre-earnings brief

— missing data

Signals & dispatch

peak dispatch · —

Composite-score breakdown

Synthesis

Business

JVM Co Ltd (054950.KQ) is a South Korean company engaged in the Advanced Medical Equipment & Technology industry within the broader Healthcare Services & Equipment sector. The firm operates primarily through a product-sale revenue model, focusing on the development and distribution of advanced medical devices. It is listed on the KOSDAQ exchange. Specific details regarding operating segments and geographic revenue breakdowns are not available.

Classification92 %

SectorHealthcare

Business sectorHealthcare Services & Equipment

IndustryAdvanced Medical Equipment & Technology

AI synthesis

GENERATED

JVM Co Ltd maintains a strong capital structure with a debt-to-equity ratio of 0.14, indicating a conservative leverage profile. The company's liquidity position is moderate, with a current ratio of 2.65, suggesting it can cover short-term obligations but has limited excess liquidity. Free cash flow of 22,387,633,860 KRW supports operational flexibility and potential reinvestment.

Profitability metrics show a return on equity (ROE) of 12.12% and a return on assets (ROA) of 8.88%, both exceeding the industry median for Advanced Medical Equipment & Technology firms. This suggests JVM Co Ltd is generating returns above the sector average.

The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification. This concentration increases exposure to sector-specific risks and regional economic shifts.

JVM Co Ltd reported revenue of 173,129,219,710 KRW in the latest period, with no prior-year data provided. Analysts project a stable outlook, with a mean price target of 34,333.33 KRW and a median of 35,000.00 KRW.

The company faces moderate liquidity risk due to negative net cash after subtracting total debt. Dilution risk is low, with no near-term pressure from share issuance or convertible instruments.

No recent filings or transcripts were provided in the input data to inform recent events or strategic shifts.

Key takeaways

JVM Co Ltd maintains a conservative debt-to-equity ratio of 0.14, indicating a strong balance sheet.
ROE of 12.12% and ROA of 8.88% suggest the company is outperforming the industry median in profitability.
Revenue is concentrated in a single business segment, increasing exposure to sector-specific risks.
Analysts project a stable outlook with a mean price target of 34,333.33 KRW.
The company faces moderate liquidity risk due to negative net cash after subtracting total debt.

Bull / Bear case

Generated · model-assisted

— missing data

In focus — financials by report

Valuation

Market price

$23 150,00

Market cap

—

Enterprise valueⓘ

—

P/Eⓘ

—

Non-GAAP P/Eⓘ

—

EV / Revenueⓘ

—

EV / Op incomeⓘ

—

EV / OCFⓘ

—

P / Bⓘ

—

P / Tangible bookⓘ

—

Tangible book

$233.95B

Net cashⓘ

-$24.63B

Current ratioⓘ

2.6

Debt / equityⓘ

0.1

ROAⓘ

8.9%

ROEⓘ

12.1%

Cash conversionⓘ

107.0%

CapEx / revenueⓘ

-2.8%

SBC / revenueⓘ

—

Dilution ratioⓘ

0.0%

Revenue by segment

Business relationships

— missing data

Supply chain

— missing data

Peer comparison

— missing data

Market position

Stress test

— missing data

Predictor forecast

Next quarternear-term

Earnings · next quarterconf 45 %

EPS

Consensus EPS

2 902,33

Predicted surprise

+0,00

Beat probability

45 %

Analysts

Other metrics

Revenue

—

no estimate

Segment revenue

—

no estimate

Margin

—

no estimate

Segment margin

—

no estimate

as of 2026-05-20 · Earnings Surprise V1

Period note: consensus is not fiscal-period-aligned at source — read as consensus vs the last reported actual, not a calibrated same-quarter surprise.

Full fiscal year~1 year ahead

Full fiscal year · our forecast vs guidance vs consensus

Metric	Our forecast	Guidance	Consensus
EPS	—no estimate	—no estimate	2 902,33
Revenue	—no estimate	—no estimate	186,9B KRW
Operating income	—no estimate	—no estimate	39,1B KRW

Full-year consensus mean (period as reported by source) · consensus in KRW. Company-level full-year forecast and management guidance are not yet modelled at scale — shown as "no estimate", never inferred.

Probabilistic model output — not investment advice. · generated 2026-08-04

Options

— missing data

Short squeeze

— missing data

Earnings-call key lines

— missing data

Consensus distribution

sell-side coverage

Recommendation distribution5 analysts

Strong buy3

Buy2

Hold0

Sell0

Strong sell0

12-month price target$34 333,33 · Median $35 000,00

Low $33 000,00High $35 000,00

Operating income · consensus39,1B KRW

EPS surprise

−15,3 %

reported vs consensus · miss

Revenue surprise

−7,4 %

reported vs consensus · miss

Estimate revisions

consensus EPS · 26-week trend

— missing data

Sell-side observations

Low$33 000,00

Mean$34 333,33

Median$35 000,00

High$35 000,00

Spot$23 150,00

+48.3 %implied to mean12-month sell-side price targets · ▲ spot

Themes

— missing data

ESG

— missing data

Risk factors

Dilution riskLow

Liquidity riskMedium

Filing-based flags

Net cash is negative after subtracting total debt.

Benchmarks vs cohort

Op Margin19,2 %Above P75

Net Margin16,4 %Above P75

ROE12,1 %Above P75

Capex / Rev-2,8 %Above median

D/E0,14Below median

Cash Conv1,07Above median

Corporate actions / M&A

— missing data

FX exposure

— missing data

Comparable transactions

— missing data

Derivatives & instruments

— missing data

Actions

Set alert Open in charts

Ask Handelsavisen

— missing data

Data sources

Market data
Market data cache
Issuer disclosures
Public news
Earnings transcripts
Consensus estimates
ESG data

How metrics are computed

Dilution Ratio
(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
Net Cash
cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
Capex To Revenue
capital_expenditure / revenue
Return On Equity
net_income / total_equity
Debt To Equity
(short_term_debt + long_term_debt) / total_equity
Cash Conversion Ratio
operating_cash_flow / net_income

Source documents

JVM Co Ltd Market data — financials · 2026-05-26
JVM Co Ltd Market data — analyst estimates · 2026-05-26
JVM Co Ltd Market data — ESG · 2026-05-26

Ownership & reference

Insider activity

— missing data

Short positioning

— missing data

Geographic breakdown

— missing data

Listings · one canonical issuer all listings resolve to the canonical

054950.KQCanonical

KOSDAQ · USD

Intel & risk

PredictorBeat prob45 %Surprise+0,00Full forecast →

peak dispatch · —

OSINT findings

Dilution riskLow

Liquidity riskMedium

Net cash is negative after subtracting total debt.

Evidence & claims

From filings & derived data

— missing data

The Thread

Everything we know, in order

2026-06-30 03:38 UTCEARNINGSUpcomingForecast: earnings_forecast (90d)

2026-06-20 12:34 UTCANALYSTAnalyst coverage initiated

The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.

Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage

Analyst recommendations

At a glance

What drives this business

News & coverage

Sector rotation

Developing storylines

Analysis

Opportunity

Upcoming catalysts

Pre-earnings brief

Signals & dispatch

Composite-score breakdown

Synthesis

Bull / Bear case

In focus — financials by report

Valuation

Revenue by segment

Market share

Business relationships

Supply chain

Peer comparison

Market position

Stress test

Predictor forecast

Options

Short squeeze

Earnings-call key lines

Consensus distribution

Estimate revisions

Sell-side observations

Themes

ESG

Risk factors

Benchmarks vs cohort

Corporate actions / M&A

FX exposure

Comparable transactions

Derivatives & instruments

Actions

Ask Handelsavisen

Ownership & reference

Insider activity

Short positioning

Geographic breakdown

Intel & risk

Evidence & claims

The Thread